| Today’s Big NewsJun 27, 2025 |
| By James Waldron Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir. |
|
|
|
By Gabrielle Masson Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases. |
By Zoey Becker Investors sued CytoDyn and former executives for allegedly misleading shareholders on the status of its potential treatment for HIV and COVID-19. |
By Nick Paul Taylor Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile end for a company that pulled in hundreds of millions of dollars from investors and partners. |
|
Immune cell engagers are opening new avenues in immuno-oncology. Discover how single-cell analysis is enabling smarter, faster ICE discovery. Watch now
|
|
By Ayla Ellison,Fraiser Kansteiner In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
By Kevin Dunleavy Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established vaccine practice, recommending against the use of flu shots that contain a preservative that has been used in shots for decades. |
By Zoey Becker,Gabrielle Masson Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar commercial drugmaker it is today. Taking his place at the helm is Bill Meury, effective immediately. |
By Andrea Park A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, with Pride Month nearing its end, the vast majority have acknowledged the celebration in some way. |
By Angus Liu A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 bispecific from Harbour BioMed to develop against autoimmune diseases. AstraZeneca and Daiichi Sankyo's Datroway secured a lung cancer approval from the FDA. And more. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
